GM3 Upregulation of matrix metalloproteinase-9 possibly through PI3K, AKT, RICTOR, RHOGDI-2, and TNF-A pathways in mouse melanoma B16 cells

Adv Exp Med Biol. 2011:705:335-48. doi: 10.1007/978-1-4419-7877-6_16.

Authors

Pu Wang¹, Xiaodong Wang, Peixing Wu, Jinghai Zhang, Toshinori Sato, Sadako Yamagata, Tatsuya Yamagata

Affiliation

¹ Laboratory of Tumor Biology and Glycobiology, Shenyang Pharmaceutical Univeristy, Shenyang, 110016, PR of China.

PMID: 21618116
DOI: 10.1007/978-1-4419-7877-6_16

No abstract available

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Animals
Cell Line, Tumor
Cell Migration Assays
Cell Movement / drug effects*
Chromones / pharmacology
Enzyme Inhibitors / pharmacology
Gangliosides / chemistry
Gangliosides / metabolism
Gangliosides / pharmacology*
Gene Silencing
Matrix Metalloproteinase 9 / genetics
Matrix Metalloproteinase 9 / metabolism*
Melanoma, Experimental / genetics
Melanoma, Experimental / metabolism*
Melanoma, Experimental / pathology
Mice
Morpholines / pharmacology
Phosphatidylinositol 3-Kinases / metabolism
Phosphoinositide-3 Kinase Inhibitors*
RNA, Messenger / analysis
RNA, Small Interfering / metabolism
RNA, Small Interfering / pharmacology
Reverse Transcriptase Polymerase Chain Reaction
Up-Regulation

Substances

Chromones
Enzyme Inhibitors
Gangliosides
Morpholines
Phosphoinositide-3 Kinase Inhibitors
RNA, Messenger
RNA, Small Interfering
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one
ganglioside, GD3
Matrix Metalloproteinase 9